CLSD

Clearside Biomedical, Inc. [CLSD] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CLSD Stock Summary

Top 10 Correlated ETFs

CLSD

Top 10 Correlated Stocks

CLSD

In the News

CLSD Financial details

Company Rating
-
Market Cap
93.4M
Income
-36.33M
Revenue
8.23M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.18
Forward P/E
-
PEG
-7.14
P/S
39.8
P/B
-6.8
P/C
-
P/FCF
-3.39
Quick Ratio
5.09
Current Ratio
5.28
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.59
EPS next Y
-
EPS next Q
-
EPS this Y
-7.02%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-7.9%
Revenue last 5Y
30.5%
Revenue Q/Q
638.65%
EPS Q/Q
-48.4%
-
-
-
-
SMA20
11.83%
SMA50
-0.95%
SMA100
-14.75%
Inst Own
-
Inst Trans
-
ROA
-116%
ROE
3551%
ROC
-1.05%
Gross Margin
75%
Oper. Margin
-1357%
Profit Margin
-1813%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.65-2.12
52W High
-
52W Low
-
RSI
43.06
Rel Volume
0.62
Avg Volume
362.29K
Volume
223.91K
Perf Week
-11.21%
Perf Month
-3.55%
Perf Quarter
-5%
Perf Half Y
-5.94%
-
-
-
-
Beta
2.326
-
-
Volatility
0.04%, 0.06%
Prev Close
-7.77%
Price
0.95
Change
-9.52%

Something similar

Top by Market Cap
0YXG.L
V
AVGO
TL0.DE
JPM
Top Correlated ETFs
IZRL
EAHG.L
PSIL
EPU
ZMBS.TO
Top Correlated Stocks
CRTO
MWA
0I4T.L
ZIP
VCSA
Similar Market Cap
BIOWKS.ST
CLSD
0996.HK
SOWG
SVR.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 362.29K
  • Market Capitalization 93.4M
  • Employee 30
  • CEO Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
  • Headquarters Alpharetta,GA,US
  • IPO Date 2016-06-02
  • Website https://www.clearsidebio.com

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.